We are live on ! Find out more
TLSI icon

TriSalus Life Sciences
TLSI

36 hedge funds and large institutions have $16.9M invested in TriSalus Life Sciences in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,000% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

37% more capital invested

Capital invested by funds: $12.4M → $16.9M (+$4.58M)

20% more funds holding

Funds holding: 30 → 36 (+6)

1.97% more ownership

Funds ownership: 8.09% → 10.06% (+2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
36
Holders Change
+6
Holders Change %
+20%
% of All Funds
0.48%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
12
Increased
11
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$4.33M
2
Millennium Management
Millennium Management
New York
+$281K
3
Goldman Sachs
Goldman Sachs
New York
+$180K
4
Citadel Advisors
Citadel Advisors
Florida
+$142K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$81.4K

Top Sellers

Rank Fund Capital Flow
1
DFO
Duquesne Family Office
New York
-$2.14M
2
AGC
Angelo Gordon & Co
New York
-$54.4K
3
EAM
Exos Asset Management
New York
-$18.1K
4
WAM
Wolverine Asset Management
Illinois
-$5.17K
5
TRCT
Tower Research Capital (TRC)
New York
-$2.78K
Name Holding Trade Value Shares
Change 		Change in
Stake
GGHC
1
Gilder Gagnon Howe & Co
New York
$4.57M +$4.33M +812,937 +5,638%
WAP
2
Wealthcare Advisory Partners
Pennsylvania
$3.55M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.69M +$55K +10,326 +2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$1.21M +$81.4K +15,287 +7%
Bank of America
5
Bank of America
North Carolina
$1.02M +$37.7K +7,086 +4%
Millennium Management
6
Millennium Management
New York
$736K +$281K +52,842 +66%
GL
7
Graypoint LLC
New York
$664K – – –
BCM
8
Bridgeway Capital Management
Texas
$359K – – –
MP
9
MSD Partners
New York
$221K – – –
Northern Trust
10
Northern Trust
Illinois
$220K +$41.6K +7,814 +24%
Goldman Sachs
11
Goldman Sachs
New York
$187K +$180K +33,900 New
BlackRock
12
BlackRock
New York
$167K – – –
CCM
13
Connective Capital Management
California
$161K +$5.8K +1,090 +4%
Citadel Advisors
14
Citadel Advisors
Florida
$147K +$142K +26,580 New
VI
15
Vestcor Inc
New Brunswick, Canada
$129K – – –
CWM
16
Connecticut Wealth Management
Connecticut
$123K – – –
State Street
17
State Street
Massachusetts
$112K – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$112K +$36.2K +6,800 +51%
Cambridge Investment Research Advisors
19
Cambridge Investment Research Advisors
Iowa
$86K – – –
Lido Advisors
20
Lido Advisors
California
$78.4K +$921 +173 +1%
HF
21
HRT Financial
New York
$75K +$72.7K +13,657 New
Balyasny Asset Management
22
Balyasny Asset Management
Illinois
$59.6K +$57.5K +10,804 New
TSS
23
Two Sigma Securities
New York
$58.5K +$56.4K +10,596 New
Charles Schwab
24
Charles Schwab
California
$55.2K +$53.2K +10,000 New
Prudential Financial
25
Prudential Financial
New Jersey
$55.2K +$53.2K +10,000 New
1
2

TLSI Hedge Fund Activity: Q1 2025 in Review

36 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q1 2025, worth a combined $16.9M — up 37% from $12.4M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new TLSI positions and 6 closed out — a net gain of 6 holders — while 11 added to existing stakes and 1 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $4.33M. The largest seller was Duquesne Family Office, exiting entirely with an estimated $2.14M sold.

  • 36 institutional investors held TriSalus Life Sciences (TLSI) as of Q1 2025, up from 30 in Q4 2024.
  • Funds reported $16.9M of TriSalus Life Sciences stock for Q1 2025, up 37% quarter-over-quarter.
  • 12 funds opened new TriSalus Life Sciences positions in Q1 2025 and 6 closed out, a net change of +6 holders.
  • The largest TriSalus Life Sciences buyer in Q1 2025 was Gilder Gagnon Howe & Co, an estimated $4.33M added.
  • The largest TriSalus Life Sciences seller in Q1 2025 was Duquesne Family Office, an estimated $2.14M sold.

Based on aggregated 13F filings for Q1 2025.